FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306-Reference-Cited by-同舟云学术

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306

Published:2012-07 Issue:7 Volume:23 Page:1693-1699
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Stintzing S.,Fischer von Weikersthal L.,Decker T.,Vehling-Kaiser U.,Jäger E.,Heintges T.,Stoll C.,Giessen C.,Modest D.P.,Neumann J.,Jung A.,Kirchner T.,Scheithauer W.,Heinemann V.

Funder

Merck Serono GmbH

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/7/1693/16703451/mdr571.pdf

Reference18 articles.

1. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer;Van Cutsem;N Engl J Med,2009

2. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer;Bokemeyer;J Clin Oncol,2009

3. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004